Evanthia Olympia Madelli
Research Subjects
Research Interests
Evanthia Olympia Madelli has a total of 328 co-authors. Here are the top co-authors by number of shared publications:
- Tiffany Boughtwood
Australian Genomics, Parkville, Australia
7 shared publications - Mathew Wallis
Tasmanian Clinical Genetics Service, Tasmanian Health Service, Hobart, Australia
4 shared publications - Edwin Philip Kirk
Genomics Laboratory New South Wales Health Pathology Randwick New South Wales Australia
3 shared publications - Julie McGaughran
Genetic Health Queensland, Royal Brisbane and Women's Hospital, Herston, QLD, Australia; School of Medicine, The University of Queensland St Lucia, Brisbane, QLD, Australia
3 shared publications - Leslie Burnett
Garvan Institute of Medical Research, Darlinghurst Sydney, NSW 2010, Australia; School of Clinical Medicine, UNSW Medicine & Health, St Vincent's Healthcare Clinical Campus, UNSW Sydney, NSW 2010, Australia; Invitae Australia, Alexandria, NSW 2015, Australia
3 shared publications - Ainsley Janelle Newson
The University of Sydney
2 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
Establishing The Australian Undiagnosed Diseases Network (UDN-Aus); Australia’s first national rare disease diagnostic network
Background: An estimated 1 in 12 individuals across the world have a rare disease. The Undiagnosed Diseases Network International (UDNI) recommend Undiagnosed Disease Programs (UDPs) as the best approach to facilitate diagnosis and support for those affected. The Australian Undiagnosed Diseases Network (UDN-Aus) was the first National Australian UDP initiative funded by the Medical Research Future Fund’s Genomics Health Futures Mission (MRFF2007567). Aims: UDN-Aus brings together an unprecedented national collaborative network for rare disease, aiming to improve the rate of genomic diagnoses for those with undiagnosed rare genetic conditions, enabling precise, personalised care to individuals throughout Australia. Methods: The research program recruited Australians who were seen through a clinical genetics service and remained undiagnosed following clinically available genomic testing. This paper outlines the approach taken to establish a national research project at 12 clinical recruitment sites. The methods detail the funding, aims, governance, study design, population and participation process, health economic research and preliminary results, and recommendations for future sustainability and implementation. Results: The study was approved by the Royal Children’s Hospital Human Research Ethics Committee on 19 November 2021 (RCH79712), with relevant site-specific approvals at local recruitment sites. Key benefits and barriers in the establishment of UDN-Aus are outlined. Conclusion: The successful establishment of this program required several components, including meaningful and ongoing community and stakeholder engagement, strategic appointment of key operational staff, and a tailored approach to facilitate more equitable enrolment. It also highlighted several crucial areas for consideration to ensure future sustainable implementation of a national UDP. These include continued investment in Australia’s national genomic data transfer policy and infrastructure, and research ethics and governance procedures imperative for the sustainable delivery of genomic research for rare disease.
- 5 November 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
Open AccessEstablishing The Australian Undiagnosed Diseases Network (UDN-Aus); Australia’s first national rare disease diagnostic network
Background: An estimated 1 in 12 individuals across the world have a rare disease. The Undiagnosed Diseases Network International (UDNI) recommend Undiagnosed Disease Programs (UDPs) as the best approach to facilitate diagnosis and support for those affected. The Australian Undiagnosed Diseases Network (UDN-Aus) was the first National Australian UDP initiative funded by the Medical Research Future Fund’s Genomics Health Futures Mission (MRFF2007567). Aims: UDN-Aus brings together an unprecedented national collaborative network for rare disease, aiming to improve the rate of genomic diagnoses for those with undiagnosed rare genetic conditions, enabling precise, personalised care to individuals throughout Australia. Methods: The research program recruited Australians who were seen through a clinical genetics service and remained undiagnosed following clinically available genomic testing. This paper outlines the approach taken to establish a national research project at 12 clinical recruitment sites. The methods detail the funding, aims, governance, study design, population and participation process, health economic research and preliminary results, and recommendations for future sustainability and implementation. Results: The study was approved by the Royal Children’s Hospital Human Research Ethics Committee on 19 November 2021 (RCH79712), with relevant site-specific approvals at local recruitment sites. Key benefits and barriers in the establishment of UDN-Aus are outlined. Conclusion: The successful establishment of this program required several components, including meaningful and ongoing community and stakeholder engagement, strategic appointment of key operational staff, and a tailored approach to facilitate more equitable enrolment. It also highlighted several crucial areas for consideration to ensure future sustainable implementation of a national UDP. These include continued investment in Australia’s national genomic data transfer policy and infrastructure, and research ethics and governance procedures imperative for the sustainable delivery of genomic research for rare disease.
- Open Access
- 25 February 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (7) , 938-946
Individuals’ preferences for future biological sample and genomic data sharing in the Australian Reproductive Genetic Carrier Screening Project
Genomic information collected in research settings is a valuable resource that can be shared for future (secondary) research with the consent of the individual. Whether individuals participating in genomic research are comfortable with broad consent and all research sharing scenarios is largely unknown. The Australian Reproductive Genetic Carrier Screening Project (Mackenzie’s Mission) investigated the feasibility and acceptability of population reproductive carrier screening for severe recessive genetic conditions occurring in childhood. Enrolment and consent for participation was completed digitally using an online Portal or REDCap. Consent included an option to complete ten specific questions about preferences for future research use of samples and data. Preferences for future research were completed by 23.5% (4288) of individuals. The remaining 76.5% gave broad consent to data sharing. Those who chose to complete the questions shared similar demographics to the rest of the cohort. Individuals were most permissive of sharing with not-for-profit (78.0%) and university (78.2%) research organisations, for general (79.8%) and health / medical / biomedical research (82.2%). People were less likely to consent for use by governments (59.2%) and commercial organisations (33.7%). Nearly 60% of people want to be notified every time their data is shared. Updates to consent preferences were made 1785 times, by 282 people. This study supports the need for research programmes to facilitate flexible models of consent, including specific and dynamic consent. It also demonstrates a scalable model in which participant-led choices contribute to reduced ambiguity about data sharing permissions.
- 25 February 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (7) , 938-946
Open AccessIndividuals’ preferences for future biological sample and genomic data sharing in the Australian Reproductive Genetic Carrier Screening Project
Genomic information collected in research settings is a valuable resource that can be shared for future (secondary) research with the consent of the individual. Whether individuals participating in genomic research are comfortable with broad consent and all research sharing scenarios is largely unknown. The Australian Reproductive Genetic Carrier Screening Project (Mackenzie’s Mission) investigated the feasibility and acceptability of population reproductive carrier screening for severe recessive genetic conditions occurring in childhood. Enrolment and consent for participation was completed digitally using an online Portal or REDCap. Consent included an option to complete ten specific questions about preferences for future research use of samples and data. Preferences for future research were completed by 23.5% (4288) of individuals. The remaining 76.5% gave broad consent to data sharing. Those who chose to complete the questions shared similar demographics to the rest of the cohort. Individuals were most permissive of sharing with not-for-profit (78.0%) and university (78.2%) research organisations, for general (79.8%) and health / medical / biomedical research (82.2%). People were less likely to consent for use by governments (59.2%) and commercial organisations (33.7%). Nearly 60% of people want to be notified every time their data is shared. Updates to consent preferences were made 1785 times, by 282 people. This study supports the need for research programmes to facilitate flexible models of consent, including specific and dynamic consent. It also demonstrates a scalable model in which participant-led choices contribute to reduced ambiguity about data sharing permissions.
- 19 December 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (4) , 476-484
Health professionals contacting patients’ relatives directly about genetic risk (with patient consent): current clinical practice and perspectives
Genetic testing can provide risk information to individuals and their blood relatives. Cascade testing uptake by at-risk relatives is n = 59/81; laboratory n = 19/23). Most clinical services (83.3%) agreed it would be beneficial to contact at-risk relatives directly. However, the majority (80.4%) do not routinely contact relatives directly, with inadequate resources (80.0%) and privacy concerns (62.2%) cited as primary reasons. If direct contact methods were used, most clinical services (65.4%) prefer a letter which includes specific information about the genetic condition. Most clinical (86.5%) and laboratory (88.2%) services saw benefit in the development of a national clinical guideline for HPs regarding direct contact. This study confirms that most clinical genetics services would see benefits to being able to assist patients by contacting relatives directly about their potential genetic risk. Our findings highlight the need for a national clinical guideline clarifying HPs’ legal and privacy obligations, and provide an opportunity for clinical services to reconsider their allocation of resources to prioritise assisting patients with risk notification.
- 19 December 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (4) , 476-484
Health professionals contacting patients’ relatives directly about genetic risk (with patient consent): current clinical practice and perspectives
Genetic testing can provide risk information to individuals and their blood relatives. Cascade testing uptake by at-risk relatives is n = 59/81; laboratory n = 19/23). Most clinical services (83.3%) agreed it would be beneficial to contact at-risk relatives directly. However, the majority (80.4%) do not routinely contact relatives directly, with inadequate resources (80.0%) and privacy concerns (62.2%) cited as primary reasons. If direct contact methods were used, most clinical services (65.4%) prefer a letter which includes specific information about the genetic condition. Most clinical (86.5%) and laboratory (88.2%) services saw benefit in the development of a national clinical guideline for HPs regarding direct contact. This study confirms that most clinical genetics services would see benefits to being able to assist patients by contacting relatives directly about their potential genetic risk. Our findings highlight the need for a national clinical guideline clarifying HPs’ legal and privacy obligations, and provide an opportunity for clinical services to reconsider their allocation of resources to prioritise assisting patients with risk notification.
- 17 December 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (4) , 485-495
Patients’ perspectives regarding health professionals contacting their relatives about genetic risk directly (with patient consent)
Genetic testing of blood relatives of individuals at high risk of dominant conditions has significant preventive health benefits. However, cascade testing uptake is n = 363; research n = 79). Clinical patients self-categorised as 49.0% directly-contacted and 51.0% referred. Overall, the majority of patients had no privacy concerns about direct-contact methods (direct-contact 97%; referred 77%; research 76%). Less than 5% of the combined cohort (n = 19/442) reported significant concerns. The most prevalent concerns were the need for consent to provide HPs with relatives’ contact details, and a patient preference to notify relatives before HP contact. Other key findings include preferences about contact methods, including that most patients who received a letter from a genetics service preferred a letter with specific information about the familial genetic condition (n = 141/149; 94.6%) than one with general information about genetic risk. Our findings indicate Australian patients support HPs using direct-contact methods to assist with risk communication to relatives. Findings also identify concerns to be addressed in the design of direct-contact programs.
- 17 December 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (4) , 485-495
Patients’ perspectives regarding health professionals contacting their relatives about genetic risk directly (with patient consent)
Genetic testing of blood relatives of individuals at high risk of dominant conditions has significant preventive health benefits. However, cascade testing uptake is n = 363; research n = 79). Clinical patients self-categorised as 49.0% directly-contacted and 51.0% referred. Overall, the majority of patients had no privacy concerns about direct-contact methods (direct-contact 97%; referred 77%; research 76%). Less than 5% of the combined cohort (n = 19/442) reported significant concerns. The most prevalent concerns were the need for consent to provide HPs with relatives’ contact details, and a patient preference to notify relatives before HP contact. Other key findings include preferences about contact methods, including that most patients who received a letter from a genetics service preferred a letter with specific information about the familial genetic condition (n = 141/149; 94.6%) than one with general information about genetic risk. Our findings indicate Australian patients support HPs using direct-contact methods to assist with risk communication to relatives. Findings also identify concerns to be addressed in the design of direct-contact programs.
- Top Cited Papers
- 21 November 2024
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 391 (20) , 1877-1889
Nationwide, Couple-Based Genetic Carrier Screening
Genomic sequencing technology allows for identification of reproductive couples with an increased chance, as compared with that in the general population, of having a child with an autosomal recessive or X-linked genetic condition. We investigated the feasibility, acceptability, and outcomes of a nationwide, couple-based genetic carrier screening program in Australia as part of the Mackenzie's Mission project. Health care providers offered screening to persons before pregnancy or early in pregnancy. The results obtained from testing at least 1281 genes were provided to the reproductive couples. We aimed to ascertain the psychosocial effects on participants, the acceptability of screening to all participants, and the reproductive choices of persons identified as having an increased chance of having a child with a condition for which we screened. Among 10,038 reproductive couples enrolled in the study, 9107 (90.7%) completed screening, and 175 (1.9%) were newly identified as having an increased chance of having a child with a genetic condition for which we screened. These conditions involved pathogenic variants in 90 different genes; 74.3% of the conditions were autosomal recessive. Three months after receiving the results, 76.6% of the couples with a newly identified increased chance had used or planned to use reproductive interventions to avoid having an affected child. Those newly identified as having an increased chance had greater anxiety than those with a low chance. The median level of decisional regret was low in all result groups, and 98.9% of participants perceived screening to be acceptable. Couple-based reproductive genetic carrier screening was largely acceptable to participants and was used to inform reproductive decision making. The delivery of screening to a diverse and geographically dispersed population was feasible. (Funded by the Medical Research Future Fund of the Australian government; ClinicalTrials.gov number, NCT04157595.).
- 21 November 2024
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 391 (20) , 1877-1889
Top Cited PapersNationwide, Couple-Based Genetic Carrier Screening
Genomic sequencing technology allows for identification of reproductive couples with an increased chance, as compared with that in the general population, of having a child with an autosomal recessive or X-linked genetic condition. We investigated the feasibility, acceptability, and outcomes of a nationwide, couple-based genetic carrier screening program in Australia as part of the Mackenzie's Mission project. Health care providers offered screening to persons before pregnancy or early in pregnancy. The results obtained from testing at least 1281 genes were provided to the reproductive couples. We aimed to ascertain the psychosocial effects on participants, the acceptability of screening to all participants, and the reproductive choices of persons identified as having an increased chance of having a child with a condition for which we screened. Among 10,038 reproductive couples enrolled in the study, 9107 (90.7%) completed screening, and 175 (1.9%) were newly identified as having an increased chance of having a child with a genetic condition for which we screened. These conditions involved pathogenic variants in 90 different genes; 74.3% of the conditions were autosomal recessive. Three months after receiving the results, 76.6% of the couples with a newly identified increased chance had used or planned to use reproductive interventions to avoid having an affected child. Those newly identified as having an increased chance had greater anxiety than those with a low chance. The median level of decisional regret was low in all result groups, and 98.9% of participants perceived screening to be acceptable. Couple-based reproductive genetic carrier screening was largely acceptable to participants and was used to inform reproductive decision making. The delivery of screening to a diverse and geographically dispersed population was feasible. (Funded by the Medical Research Future Fund of the Australian government; ClinicalTrials.gov number, NCT04157595.).
- Open Access
- 3 May 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (7) , 887-897
Genomic Testing in Patients with Kidney Failure of an Unknown Cause
Key Points: Twenty-five percent of those with unexplained kidney failure have a monogenic cause. Whole genome sequencing with broad gene panel analysis is a feasible diagnostic approach in nephrology. Background: The cause of kidney failure is unknown in approximately 10% of patients with stage 5 chronic kidney disease (CKD). For those who first present to nephrology care with kidney failure, standard investigations of serology, imaging, urinalysis, and kidney biopsy are limited differentiators of etiology. We aimed to determine the diagnostic utility of whole genome sequencing (WGS) with analysis of a broad kidney gene panel in patients with kidney failure of unknown cause. Methods: We prospectively recruited 100 participants who reached CKD stage 5 at the age of ≤50 years and had an unknown cause of kidney failure after standard investigation. Clinically accredited WGS was performed in this national cohort after genetic counseling. The primary analysis was targeted to 388 kidney-related genes with second-tier, genome-wide, and mitochondrial analysis. Results: The cohort was 61% male and the average age of participants at stage 5 CKD was 32 years (9 months to 50 years). A genetic diagnosis was made in 25% of participants. Disease-causing variants were identified across autosomal dominant tubulointerstitial kidney disease (6), glomerular disorders (4), ciliopathies (3), tubular disorders (2), Alport syndrome (4), and mitochondrial disease (1). Most diagnoses (80%) were in autosomal dominant, X-linked, or mitochondrial conditions (UMOD; COL4A5; INF2; CLCN5; TRPC6; COL4A4; EYA1; HNF1B; WT1; NBEA; m.3243A>G). Participants with a family history of CKD were more likely to have a positive result (odds ratio, 3.29; 95% confidence interval, 1.10 to 11.29). Thirteen percent of participants without a CKD family history had a positive result. In those who first presented in stage 5 CKD, WGS with broad analysis of a curated kidney disease gene panel was diagnostically more informative than kidney biopsy, with biopsy being inconclusive in 24 of the 25 participants. Conclusions: In this prospectively ascertained Australian cohort, we identified a genetic diagnosis in 25% of patients with kidney failure of unknown cause.
- 3 May 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (7) , 887-897
Open AccessGenomic Testing in Patients with Kidney Failure of an Unknown Cause
Key Points: Twenty-five percent of those with unexplained kidney failure have a monogenic cause. Whole genome sequencing with broad gene panel analysis is a feasible diagnostic approach in nephrology. Background: The cause of kidney failure is unknown in approximately 10% of patients with stage 5 chronic kidney disease (CKD). For those who first present to nephrology care with kidney failure, standard investigations of serology, imaging, urinalysis, and kidney biopsy are limited differentiators of etiology. We aimed to determine the diagnostic utility of whole genome sequencing (WGS) with analysis of a broad kidney gene panel in patients with kidney failure of unknown cause. Methods: We prospectively recruited 100 participants who reached CKD stage 5 at the age of ≤50 years and had an unknown cause of kidney failure after standard investigation. Clinically accredited WGS was performed in this national cohort after genetic counseling. The primary analysis was targeted to 388 kidney-related genes with second-tier, genome-wide, and mitochondrial analysis. Results: The cohort was 61% male and the average age of participants at stage 5 CKD was 32 years (9 months to 50 years). A genetic diagnosis was made in 25% of participants. Disease-causing variants were identified across autosomal dominant tubulointerstitial kidney disease (6), glomerular disorders (4), ciliopathies (3), tubular disorders (2), Alport syndrome (4), and mitochondrial disease (1). Most diagnoses (80%) were in autosomal dominant, X-linked, or mitochondrial conditions (UMOD; COL4A5; INF2; CLCN5; TRPC6; COL4A4; EYA1; HNF1B; WT1; NBEA; m.3243A>G). Participants with a family history of CKD were more likely to have a positive result (odds ratio, 3.29; 95% confidence interval, 1.10 to 11.29). Thirteen percent of participants without a CKD family history had a positive result. In those who first presented in stage 5 CKD, WGS with broad analysis of a curated kidney disease gene panel was diagnostically more informative than kidney biopsy, with biopsy being inconclusive in 24 of the 25 participants. Conclusions: In this prospectively ascertained Australian cohort, we identified a genetic diagnosis in 25% of patients with kidney failure of unknown cause.
- Open Access
- 14 September 2023
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (1) , 61-68
Evaluation of CTRL: a web application for dynamic consent and engagement with individuals involved in a cardiovascular genetic disorders cohort
There has been keen interest in whether dynamic consent should be used in health research but few real-world studies have evaluated its use. Australian Genomics piloted and evaluated CTRL (‘control’), a digital consent tool incorporating granular, dynamic decision-making and communication for genomic research. Individuals from a Cardiovascular Genetic Disorders Flagship were invited in person (prospective cohort) or by email (retrospective cohort) to register for CTRL after initial study recruitment. Demographics, consent choices, experience surveys and website analytics were analysed using descriptive statistics. Ninety-one individuals registered to CTRL (15.5% of the prospective cohort and 11.8% of the retrospective cohort). Significantly more males than females registered when invited retrospectively, but there was no difference in age, gender, or education level between those who did and did not use CTRL. Variation in individual consent choices about secondary data use and return of results supports the desirability of providing granular consent options. Robust conclusions were not drawn from satisfaction, trust, decision regret and knowledge outcome measures: differences between CTRL and non-CTRL cohorts did not emerge. Analytics indicate CTRL is acceptable, although underutilised. This is one of the first studies evaluating uptake and decision making using online consent tools and will inform refinement of future designs.
- 14 September 2023
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (1) , 61-68
Open AccessEvaluation of CTRL: a web application for dynamic consent and engagement with individuals involved in a cardiovascular genetic disorders cohort
There has been keen interest in whether dynamic consent should be used in health research but few real-world studies have evaluated its use. Australian Genomics piloted and evaluated CTRL (‘control’), a digital consent tool incorporating granular, dynamic decision-making and communication for genomic research. Individuals from a Cardiovascular Genetic Disorders Flagship were invited in person (prospective cohort) or by email (retrospective cohort) to register for CTRL after initial study recruitment. Demographics, consent choices, experience surveys and website analytics were analysed using descriptive statistics. Ninety-one individuals registered to CTRL (15.5% of the prospective cohort and 11.8% of the retrospective cohort). Significantly more males than females registered when invited retrospectively, but there was no difference in age, gender, or education level between those who did and did not use CTRL. Variation in individual consent choices about secondary data use and return of results supports the desirability of providing granular consent options. Robust conclusions were not drawn from satisfaction, trust, decision regret and knowledge outcome measures: differences between CTRL and non-CTRL cohorts did not emerge. Analytics indicate CTRL is acceptable, although underutilised. This is one of the first studies evaluating uptake and decision making using online consent tools and will inform refinement of future designs.
- Open Access
- 28 October 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (11) , 1781
The Australian Reproductive Genetic Carrier Screening Project (Mackenzie’s Mission): Design and Implementation
Reproductive genetic carrier screening (RGCS) provides people with information about their chance of having children with autosomal recessive or X-linked genetic conditions, enabling informed reproductive decision-making. RGCS is recommended to be offered to all couples during preconception or in early pregnancy. However, cost and a lack of awareness may prevent access. To address this, the Australian Government funded Mackenzie’s Mission—the Australian Reproductive Genetic Carrier Screening Project. Mackenzie’s Mission aims to assess the acceptability and feasibility of an easily accessible RGCS program, provided free of charge to the participant. In study Phase 1, implementation needs were mapped, and key study elements were developed. In Phase 2, RGCS is being offered by healthcare providers educated by the study team. Reproductive couples who provide consent are screened for over 1200 genes associated with >750 serious, childhood-onset genetic conditions. Those with an increased chance result are provided comprehensive genetic counseling support. Reproductive couples, recruiting healthcare providers, and study team members are also invited to complete surveys and/or interviews. In Phase 3, a mixed-methods analysis will be undertaken to assess the program outcomes, psychosocial implications and implementation considerations alongside an ongoing bioethical analysis and a health economic evaluation. Findings will inform the implementation of an ethically robust RGCS program.
- 28 October 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (11) , 1781
Open AccessThe Australian Reproductive Genetic Carrier Screening Project (Mackenzie’s Mission): Design and Implementation
Reproductive genetic carrier screening (RGCS) provides people with information about their chance of having children with autosomal recessive or X-linked genetic conditions, enabling informed reproductive decision-making. RGCS is recommended to be offered to all couples during preconception or in early pregnancy. However, cost and a lack of awareness may prevent access. To address this, the Australian Government funded Mackenzie’s Mission—the Australian Reproductive Genetic Carrier Screening Project. Mackenzie’s Mission aims to assess the acceptability and feasibility of an easily accessible RGCS program, provided free of charge to the participant. In study Phase 1, implementation needs were mapped, and key study elements were developed. In Phase 2, RGCS is being offered by healthcare providers educated by the study team. Reproductive couples who provide consent are screened for over 1200 genes associated with >750 serious, childhood-onset genetic conditions. Those with an increased chance result are provided comprehensive genetic counseling support. Reproductive couples, recruiting healthcare providers, and study team members are also invited to complete surveys and/or interviews. In Phase 3, a mixed-methods analysis will be undertaken to assess the program outcomes, psychosocial implications and implementation considerations alongside an ongoing bioethical analysis and a health economic evaluation. Findings will inform the implementation of an ethically robust RGCS program.